Health

Nano Labs Announces Receipt of Deficiency Letters from Nasdaq

HANGZHOU, China, July 12, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider in China, today announced that it received a notification letter datedJuly 11, 2024 (the "Deficiency Le...

2024-07-13 04:30

Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJuly 10, 2024, NASDAQ notified the Company that it has determined that for the...

2024-07-12 20:30 982

Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress

TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa Biosciences' new drug Pidnarulex (CX-5461) has demonstrated efficacy in treating various solid tumors with BRCA2 or PALB2 gene defects. The abstract of this clinical trial has been selected for presentation at the 2024 European Society fo...

2024-07-12 19:00 1246

Shenzhen Hosts the 2nd AGP&DTx Summit Forum: Advancing Digital Therapeutics in Diabetes Management

SHENZHEN, China, July 12, 2024 /PRNewswire/ -- On July 5th, the 2nd Ambulatory Glucose Profile (AGP) & Digital Therapeutics (DTx), led by the National Innovation Center for Advanced Medical Devices, sponsored by China AGP and DTx Digital Therapeutics R&D Center ("R&D Center"), co-sponsored by She...

2024-07-12 17:09 1211

MGI Tech Launches DNBSEQ-G400RS FluoXpert in the APAC Region at Medlab Asia & Asia Health 2024

BANGKOK, July 12, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, today launched DNBSEQ-G400RS FluoXpert in the APAC region and opened early access to the platform at Medlab Asia & Asia Health 2024...

2024-07-12 16:57 1138

Sirnaomics Announces Completion of IND-Enabling Studies of Safety and Efficacy for STP125G with NHP Models, Targeting ApoC3 for Treatment of Cardiovascular Diseases

HONG KONG, GERMANTOWN, Md. and SUZHOU, China, July 12, 2024 /PRNewswire/ -- Sirnaomics Ltd.(the "Company", Stock Code: 2257.HK, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, an...

2024-07-12 16:53 1357

Smartee Denti-Technology Debuts Themed Airplane with Spring Airlines

SHANGHAI, July 12, 2024 /PRNewswire/ -- Smartee Denti-Technology, in partnership with Spring Airlines, unveiled its inaugural themed airplane at Shanghai Hongqiao International Airport. The event was part of Smartee's 20th-anniversary celebrations.

2024-07-12 15:26 888

Allianz Partners supports Paris 2024 with medical assistance and repatriation services

The 155,000 athletes, volunteers, and members of the Olympic and Paralympic Family will benefit from Allianz Partners' medical assistance and repatriation services during the Olympic and Paralympic Games Paris 2024. SINGAPORE, July 12, 2024 /PRNewswire/ -- Allianz Partners, a world leader in ass...

2024-07-12 07:00 1793

CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE

BEIJING, July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it plans to change the ratio of its American d...

2024-07-12 04:00 1592

Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation

SEOUL, South Korea, July 11, 2024 /PRNewswire/ -- Medit, a global leader in dental 3D scanners and digital dentistry solutions, has appointedHan Ryu as its new CEO. Ryu brings with him over three decades of senior management experience in global medical device and healthcare companies, including ...

2024-07-11 21:00 1654

Origin Agritech Chairman and CEO Dr. Gengchen Han Provides Business Updates and Answers Questions from Investors

BEIJING, July 11, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, provided a business update from Dr. Gengchen Han, Chairman and CEO of Origin Agritech. Dear Shareholders, We are pleased to provide you with...

2024-07-11 21:00 2170

CUHK identifies novel gut microbiome biomarkers to facilitate diagnosis of autism spectrum disorders

Pilot clinical study shows modulation of gut microbiome alleviates anxiety symptoms  HONG KONG, July 11, 2024 /PRNewswire/ -- The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) has conducted a large cohort study among 1,627 children with and without autism spectrum di...

2024-07-11 20:55 1597

Prenetics, NASDAQ Health Sciences Company, Partners with David Beckham

* Beckham becomes a strategic investor in Prenetics * Beckham and Prenetics are co-founding partners for IM8, a new health and wellness brand LOS ANGELES, July 11, 2024 /PRNewswire/ -- Prenetics, (NASDAQ: PRE) a leading health sciences company, is proud to announce that former international...

2024-07-11 20:48 1652

First Patient Dosed in Phase I Clinical Trial of YOLT-201

SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced today the successful enrollment of the first patient in the Phase I clinical trial of YOLT-201, its independently developed in vivo g...

2024-07-11 20:11 1224

Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC

SHANGHAI, July 11, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tech...

2024-07-11 20:00 1230

Newest Version of LifeSphere® Regulatory Platform Allows Organizations to Leverage Latest GenAI Technology

End-to-end functionality helps cut skyrocketing costs of compliance & removes workflow inefficiencies * The cloud-based platform demonstrates 50%+ efficiency gains across Regulatory Operations by bringing together data, content, and processes in a single ecosystem. * Platform is interoperabl...

2024-07-11 20:00 1243

CUHK identifies novel gut microbiome biomarkers to facilitate diagnosis of autism spectrum disorders

Pilot clinical study shows modulation of gut microbiome alleviates anxiety symptoms  HONG KONG, July 11, 2024 /PRNewswire/ -- A research team from The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) has conducted a large cohort study among 1,627 children with and witho...

2024-07-11 18:36 1373

Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.

Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric anti...

2024-07-11 14:24 1435

Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.

Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric anti...

2024-07-11 14:21 1257

ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. * Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue ...

2024-07-11 14:07 1205
12345 ... 833